english
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. 2018b. J. Nucl. Med. 59, 1234?1242.

Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. Deshayes, E., Ladjohounlou, R., Le Fur, P., Pichard, A., Lozza, C., Boudousq, V., Sevestre, S., Jarlier, M., Kashani, R., Koch, J., Sosabowski, J., Foster, J., Chouin, N., Bruchertseifer, F., Morgenstern, A., Kotzki, P.-O., Navarro-Teulon, I., Pouget, J.-P., 2018b. J. Nucl. Med. 59, 1234–1242.


Retour à la liste générale
© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés